At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 337 enrolled
Drug / intervention
TAS-303 +1 moredrug
Likely dose
TAS-303 orally once daily for 8 weeksAI-extracted
Key inclusion· 5
- ✓Symptoms of Stress Urinary Incontinence for at least 12 weeks prior to study entry
- ✓At least 1 incontinence episode per day
- ✓Urinary diurnal frequency of 10 or less per day
- ✓Nocturia of 2 or less per day
Key exclusion· 6
- ✕Predominant or primary urge incontinence
- ✕Prior surgical SUI treatment
- ✕Stage II or more pelvic organ prolapse
- ✕Active urinary tract infection
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIa Study of TAS-303 in Female Patients With Stress Urinary Incontinence
In Brief
A Phase 2 clinical trial evaluating TAS-303 and Placebo for Stress Urinary Incontinence. Completed, enrolled 337 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of TAS-303 in female patients with stress urinary incontinence.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStress Urinary Incontinence
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartOct 2016
Primary CompletionApr 2018
TodayJul 2026
First PostedSep 20, 2016
Enrollment StartOct 20, 2016
Primary CompletionApr 30, 2018
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 9.8 years ago
Interventions
TAS-303drug
Oral administration for 8 weeks, once daily.
Placebodrug
Oral administration for 8 weeks, once daily.